South Africa Seeks New Vaccine Strategy After Study

A vaccine is being put on hold after a study found it offers minimal protection against mild and moderate cases of a variant first discovered in South Africa. Severe cases were not included in the study. The company is collaborating with South African leaders to determine the next steps. Meanwhile, South Africa is proceeding with Johnson and Johnson and Pfizer vaccines.

Why was the vaccine put on hold?

• It was not effective against a specific variant.

• It was not approved by the government.

• It was too expensive.

• It caused severe side effects.

What did the study reveal about the vaccine's effectiveness?

• It provided minimal protection against mild and moderate cases.

• It was not effective at all.

• It was highly effective against all cases.

• It was effective only against severe cases.

Which cases were not included in the study?

• Severe cases

• Moderate cases

• Mild cases

• All cases

What is the company doing in response to the study findings?

• Developing a new vaccine

• Ignoring the findings

• Working with South African leaders for a solution

• Discontinuing the vaccine

Which vaccines is South Africa moving forward with?

• Moderna and AstraZeneca

• Johnson & Johnson and Pfizer

• Sputnik V and Sinovac

• Covaxin and Covovax